METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) TESTING SYSTEMS MARKET ANALYSIS

Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems MarketSize and Trends

The global methicillin resistant staphylococcus aureus (MRSA) testing systems market is estimated to be valued at US$ 141.3 million in 2023 and is expected to exhibit a CAGR of 10.8% during the forecast period (2023-2030).

Figure 1. Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market Share (%), By Product Type, 2023

Among all the segmentations, the product type segment has the potential due to increasing advancements in methicillin resistant staphylococcus aureus (MRSA) testing systems. This is attributed to the accurate detecting of methicillin resistant staphylococcus aureus infection.

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market- Cross Sectional Analysis:

Key players are manufacturing new methicillin resistant staphylococcus aureus (MRSA) testing systems with advanced technology in emerging economies, and this is expected to boost demand of methicillin resistant staphylococcus aureus testing systems in North America region. For instance, in July 2021, Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced the commercial launch of KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections (ABSSSI) in a single, one hour, 1,200 mg infusion. The U.S. Food and Drug Administration approved KIMYRSA on March 12, 2021, for the treatment of adult patients with ABSSSI caused by susceptible isolates of designated gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market: Key Trends

Rising demand for POC (point of care) diagnostics in MRSA

Rising demand for POC (point of care) diagnostics in MRSA is expected to drive the market growth. The technological developments in POC devices and test procedures that enable improved diagnosis is expected to drive the market growth. For instance, in October 2020, Exagen Diagnostics, a U.S.-based commercial-stage diagnostics company that develops and sells diagnostic tests, announced the launch of the second variant validated POC (point of care) diagnostics in MRSA to detect Staphylococcus Aureus infection, which has been found to be significantly elevated in patients with infection. These kinds of developments in the healthcare system and rising health expenditures, as well as increased knowledge of advanced Staphylococcus Aureus infection treatments are fueling the methicillin resistant staphylococcus aureus (MRSA) testing market in North America.